Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. After the March 2026 patent expiry in India, eight CDSCO-approved manufacturers launched generic versions, dramatically reducing costs.
How it works
Semaglutide mimics the action of GLP-1, a naturally occurring hormone released after eating. It slows gastric emptying, increases insulin secretion in response to meals, and signals fullness to the brain.
Available brands in India (2026)
Branded original: Ozempic by Novo Nordisk (~Rs. 2,025 per weekly injection). Generic options range from Rs. 325 (Natco Semanat vial) to Rs. 510 (Sun Pharma Semaglyn pen).
Typical dose schedule
Week 1-4: 0.25mg weekly. Week 5-8: 0.5mg weekly. Week 9+: Increase up to 1.0mg or 2.0mg based on response. Never start at higher doses.